Novacyt S.A. ALNOV

EURONEXT · France · Health Technology

€0.4720-0.02 (-4.65%)

Market closed· Oct 1, 2026, 3:35 PM UTC· EUR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Novacyt S.A. ALNOV

EURONEXT · France · Health Technology

€0.4720-0.02 (-4.65%)

Market closed· Oct 1, 2026, 3:35 PM UTC· EUR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+24.37% · 6MFull-screen chart

Open €0.4900High €0.4900Low €0.4600Close €0.4720Volume 377.59K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: €0.4950
Day range: €0.4600 – €0.4900
52-week range: €0.2900 – €1.04
Volume: 377.59K
Market cap: €35.93M
Next earnings date: 2027-04-29
Avg. volume (1Y): 452.61K

Performance

1 week

-0.20%

1 month

-1.39%

3 months

+23.60%

6 months

+34.88%

Year to date

+17.86%

1 year

+2.06%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Medical Specialties
Country: France
Exchange: EURONEXT
Shares outstanding: 72.59M
ISIN: FR0010397232
Beta: 0.11

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 05, 2026

Could Illumina’s Novacyt Collaboration Framework Quietly Reshape Its Clinical Sequencing Narrative (ILMN)?

In September 2026, Novacyt S.A. announced it had entered into a five-year Master Collaboration Agreement with Illumina, creating a framework for separate project-based deals in product development and commercial collaboration. This structure gives Illumina a flexible way to tap Novacyt’s complementary expertise without committing upfront capital to specific programs, potentially broadening future genomic applications. We’ll now examine how this new Master Collaboration framework with...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.